$BDX

Polen Thomas E Jr sold $405K of BDX

Polen Thomas E Jr (Chairman, CEO and President) sold 2,764 shares of BECTON DICKINSON & CO (BDX) at $146.35 ($0.40M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Polen Thomas E Jr
Published Jun 3, 2026, 4:44 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 4:47 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BDX
Neutral
high confidence
Mentioned
$BDX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BDXNeutralLow
01

Why it matters

Because the transaction is pre-arranged and not tied to new earnings, guidance, litigation, or product/regulatory events, it is unlikely to change the company’s fundamental outlook.

02

Market read

Traders may note the disclosure for sentiment monitoring, but it does not introduce new fundamental information.

03

What to watch

The article provides no context on why the sale occurred (e.g., diversification, tax planning), which limits inference from the transaction size alone.

Relevance 6/10Novelty 3/10Timing: Filed June 3, covering a sale executed June 1

Background

The article is an SEC Form 4 disclosure of an officer/director open-market sale by Becton Dickinson’s CEO/Chairman under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$BDXNeutralHigh confidence
Context

Becton Dickinson CEO/Chairman Thomas E. Polen sold 2,764 shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; any reaction should fade unless accompanied by other company-specific news.

Evidence & confidence

The filing is an SEC Form 4 insider transaction with an explicitly pre-arranged 10b5-1 plan, providing no new operating or financial information.

Market effects

Minimal; this is company-specific insider activity without sector-wide catalyst.

None expected beyond routine US large-cap sentiment.

None expected; no international transaction or regulatory development mentioned.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can be interpreted by some traders as reduced confidence, especially if it coincides with broader valuation concerns.

Key entities

  • Becton Dickinson & Co

    Subject of the insider transaction disclosure (SEC Form 4).

  • Thomas E. Polen Jr

    Chairman, CEO and President who sold shares on June 1, 2026 under a 10b5-1 plan.

Related articles

$REPLMed

This Week at FDA: Inspection reorg, acting CBER chief eyes IND reforms, and more

FDA updates cover inspection reorganization plans, proposed IND reforms for early-stage biologics research, and accelerated approval of Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg) with Bristol Myers Squibb’s Opdivo for melanoma after PD-1 regimens. Other items include FDA workshops, Seegene EUA for an assay, and multiple drug/device recalls.

$BDXMed

Becton, Dickinson Boosts FY26 Adj. EPS Outlook - Update

Becton, Dickinson and Co. (BDX) reported third-quarter results and raised its FY2026 adjusted EPS outlook to $12.62 to $12.72 per share, from $12.52 to $12.72. The company kept its revenue growth view, expecting low single-digit plus growth and low single-digit constant-currency growth. Shares were about $172.00 premarket.

$BDXMedAI 8/10

BD Reports Third Quarter Fiscal 2026 Financial Results

BD (NYSE:BDX) reported fiscal 2026 third-quarter results ended June 30, 2026. Revenue rose to $5.0 billion, up 5.4% reported and 4.4% on an FX-neutral basis. GAAP and adjusted diluted EPS from continuing operations were $1.64 and $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion, and free cash flow rose 44.6% to $1.7 billion. BD updated full-year guidance, expecting revenue growth toward the high end and raised the adjusted EPS midpoint.